Table 2.
Prophylactic Arrhythmia Surgery
| Author, y | No. | CHD | Lesions | Outcome |
|---|---|---|---|---|
| Gonzalez Corcia et al, 2019 23 | 29 | Mainly Ebstein |
Right‐sided lesions*: 28 Biatrial lesions*: 1 |
Freedom from ATA at 1, 3, 5 y: 97%, 97%, 80% |
| Lim et al, 2017 33 | 27 | Initial LT Fontan |
|
Spontaneous MRAT: 1/27 (3.7%) at 12.6 y Inducible non‐sustained MRAT, 3/19 (11.1%) at 5.2 to 11.8 y |
| Atallah et al, 2012 20 | 15 | Initial LT Fontan | Atrial incision right atriotomy—RAVV |
Spontaneous MRAT, 0/15 (0%) at 9 y Inducible MRAT, 0/2 (0%) at 9 y |
| 14 | Initial LT Fontan | Control group (no prophylactic lesion) |
Spontaneous MRAT, 0/14 (0%) at 9.3 y Inducible MRAT, 0/5 (0%) at 9.3 y |
|
| Lukac et al, 2007 35 | 17 | Mainly ASD | Cryolesion right atriotomy—RAVV |
Spontaneous MRAT, 2/17 (12%) at 3 mo Inducible MRAT, 2/17 (12%) at 3 mo |
ASD indicates atrial septal defect; ATA, atrial tachyarrhythmias; CHD, congenital heart disease; CS, coronary sinus; LT, lateral tunnel; MRAT, macroreentrant atrial tachycardia; and RAVV, right atrioventricular valve.
Lesion locations and energy sources not further specified.